Dexmetomedine as an Adjuvant to Bupivacaine in Ultrasound Guided PECS Block

Sponsor
Menoufia University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05717114
Collaborator
(none)
96
3
9

Study Details

Study Description

Brief Summary

Regional anesthesia is an essential component of anesthesia and analgesia. It has many advantages, it decreases pain post operatively, improves patient outcome and allow early recovery and ambulation Post-operative pain following breast surgery results from injured muscles and nerves, management of acute post operative pain is a consistent factor for better outcome and patient satisfaction

Condition or Disease Intervention/Treatment Phase
  • Procedure: Pecs block
N/A

Detailed Description

All patients will be monitored by standard intraoperative monitoring that includes continuous electrocardiography (ECG), capnography, pulse oximetry, and non invasive blood pressure.

Induction of general anesthesia will be done by propofol 1.5-2 mg/kg and fentanyl 3µg/kg.

Tracheal intubation will be facilitated by administration of rocuronium 0.8 mg/kg. Anesthesia will be maintained with isoflurane 1MAC (Pecs block):the block will be performed with the patients in the supine position.The infraclavicular and axillary regions will be cleaned with antiseptic solution. the in plane technique will be used from proximal and medial to distal and lateral in an oblique manner at dermatome level T2 and T3.The puncture site was infiltrated with 2%lidocaine and once the structures is identified with Ultrasound

Study Design

Study Type:
Interventional
Anticipated Enrollment :
96 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Prospective randomized studyProspective randomized study
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Efficacy of Different Doses of Dexmetomedine as an Adjuvant to Bupivacaine in Ultrasound Guided PECS Block in Patients Undergoing Modified Radical Mastectomy
Anticipated Study Start Date :
Feb 1, 2023
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Nov 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Group I

received plan bupivacaine1ml/Kg

Procedure: Pecs block
(Pecs block):the block will be performed with the patients in the supine position.The infraclavicular and axillary regions will be cleaned with antiseptic solution. the inplane technique will be used from proximal and medial to distal and lateral in an oblique manner at dermatome level T2and T3.The puncture site was infiltrated with 2%lidocaine and once the structures is identified with ultrasound.

Active Comparator: Group II

received plain bupivacaine 1ml/Kg plus dexmetomedine0.5 µg/Kg

Procedure: Pecs block
(Pecs block):the block will be performed with the patients in the supine position.The infraclavicular and axillary regions will be cleaned with antiseptic solution. the inplane technique will be used from proximal and medial to distal and lateral in an oblique manner at dermatome level T2and T3.The puncture site was infiltrated with 2%lidocaine and once the structures is identified with ultrasound.

Active Comparator: GroupIII

received plain bupivacaine 1ml/Kg plus dexmetomedine1µg/Kg

Procedure: Pecs block
(Pecs block):the block will be performed with the patients in the supine position.The infraclavicular and axillary regions will be cleaned with antiseptic solution. the inplane technique will be used from proximal and medial to distal and lateral in an oblique manner at dermatome level T2and T3.The puncture site was infiltrated with 2%lidocaine and once the structures is identified with ultrasound.

Outcome Measures

Primary Outcome Measures

  1. postoperative pain [48 hours]

    Visual analog score for pain where 0 no pain and 10 most severe pain

Secondary Outcome Measures

  1. Total morphine consumption [48 hours]

    Mg

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • adult patients

  • aged 18-60years old

  • ASA class 1 to 3

  • scheduled for elective modified radical mastectomy

Exclusion Criteria:
  • patients refusal,

  • coagulopathies

  • concurrent anticoagulant therapy

  • allergy to local anaesthetics

  • infection at puncture site

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Menoufia University

Investigators

  • Principal Investigator: rabab M habeeb, Menofia University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
rabab Mohammad habeeb, Principal investigator, Menoufia University
ClinicalTrials.gov Identifier:
NCT05717114
Other Study ID Numbers:
  • 1/2023,ANET2-1
First Posted:
Feb 8, 2023
Last Update Posted:
Feb 8, 2023
Last Verified:
Jan 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 8, 2023